Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines

Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines

Abstract Background The introduction of combined conventional cytostatics and pathway-specific inhibitors has opened new treatment options for several cancer types including hematologic neoplasia such as leukaemias. As the detailed understanding of the combination-induced molecular effects is often...

Full description

Bibliographic Details
Main Authors: L.-M. Sklarz, Y. S. Gladbach, M. Ernst, M. Hamed, C. Roolf, S. Sender, J. Beck, E. Schütz, S. Fischer, S. Struckmann, C. Junghanss, G. Fuellen, H. Murua Escobar
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Cancer Cell International
Subjects:
PIK3-inhibition
Acute lymphoblastic leukaemia
Idelalisib
Cytostatics
Drug combinations
Cytarabine
Online Access:http://link.springer.com/article/10.1186/s12935-020-01431-4

Internet

http://link.springer.com/article/10.1186/s12935-020-01431-4

Similar Items